Publication | Open Access
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
615
Citations
17
References
2014
Year
In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy. However, there was a greater decrease in lung function during the final step of glucocorticoid withdrawal. (Funded by Boehringer Ingelheim Pharma; WISDOM ClinicalTrials.gov number, NCT00975195.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1